{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:19:37Z","timestamp":1787552377051,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pharmacogenomics (PGx) is a cornerstone of precision medicine, enabling tailored drug therapy based on an individual\u2019s genetic profile. However, public awareness, attitudes, and concerns regarding PGx testing in Saudi Arabia remain largely unexplored. This study aimed to evaluate these aspects among Saudi adults and to identify associated sociodemographic and health-related factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An exploratory, cross-sectional online survey was conducted between August and October 2025 using convenience and snowball sampling. A total of 391 eligible adults (\u226518\u202fyears, non-healthcare providers) completed an anonymous questionnaire adapted from previously published instruments. Multivariable logistic and ordered logistic regression analyses were performed to examine factors associated with PGx familiarity, attitudes, concerns, willingness to undergo testing, and consent preferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Attitudes toward PGx testing were strongly positive. Between 70 and 72% of respondents expressed comfort with PGx testing to predict medication efficacy, appropriate dosing, or side effects, and 68% were comfortable when it was recommended by a healthcare provider. The most prominent concerns were privacy breaches (34% high concern) and testing cost (44% high concern). While 71% expressed concern about paying out of pocket for the test, 83% indicated greater willingness if it were free or covered by insurance. Most participants (93%) expected prior notification by their provider, and 85% favored obtaining specific consent for PGx testing. In adjusted models, good\/excellent self-rated health was associated with lower odds for high privacy concern (aOR 0.26, 95% CI 0.11\u20130.64;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.004) and high cost concern (aOR 0.25, 0.10\u20130.62;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.003). Doctoral education was associated with a more favorable overall attitude toward pharmacogenomic testing (aOR 3.92, 1.16\u201313.28;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.028), and residence in Mecca (vs Riyadh) was associated with greater willingness if covered by insurance (aOR 4.24, 1.44\u201312.50;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.009).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Acceptance of and interest in PGx testing were high in this online volunteer sample, with privacy and cost as the main barriers. Robust privacy protective measures and integration into healthcare coverage could accelerate the adoption of precision medicine in Saudi Arabia. Findings should be interpreted with caution, given the convenience sampling design and limited generalizability to the broader population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1887596","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:31:24Z","timestamp":1787549484000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Public awareness, attitudes, and concerns regarding pharmacogenomics in the Kingdom of Saudi Arabia: an exploratory online cross-sectional survey"],"prefix":"10.3389","volume":"14","author":[{"given":"Saad A.","family":"Aldosari","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University","place":["Alkharj, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhuha","family":"Alhuthaily","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Prince Sattam Bin Abdulaziz University","place":["Alkharj, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gadah K.","family":"Alonazi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Department, Prince Sattam bin Abdulaziz University Hospital","place":["Alkharj, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Almunef","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Qassim University","place":["Buraidah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Alothman","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Prince Sattam Bin Abdulaziz University","place":["Alkharj, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/pme-2021-0064","article-title":"Attitudes toward pharmacogenetics in patients undergoing CYP2C19 testing following percutaneous coronary intervention","volume":"19","author":"Lee","year":"2022","journal-title":"Pers Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1364221","DOI":"10.3389\/fpubh.2024.1364221","article-title":"Forging the path to precision medicine in Qatar: a public health perspective on pharmacogenomics initiatives","volume":"12","author":"Bastaki","year":"2024","journal-title":"Front Public Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1111\/cts.13637","article-title":"Assessing pharmacogenomic literacy in China through validation of the Chinese version of the Minnesota assessment of Pharmacogenomic literacy","volume":"16","author":"Zhang","year":"2023","journal-title":"Clin Transl Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/jpm12101615","article-title":"Public attitudes toward pharmacogenomic testing and establishing a statewide pharmacogenomics database in the state of Minnesota","volume":"12","author":"Zhang","year":"2022","journal-title":"J Pers Med."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"595219","DOI":"10.3389\/fphar.2020.595219","article-title":"Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines","volume":"11","author":"Abdullah-Koolmees","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e1417","DOI":"10.1002\/wsbm.1417","article-title":"PharmGKB: a worldwide resource for pharmacogenomic information","volume":"10","author":"Barbarino","year":"2018","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"724311","DOI":"10.3389\/fphar.2021.724311","article-title":"Adoption of Pharmacogenomic testing: a marketing perspective","volume":"12","author":"Koufaki","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FPC.0000000000000547","article-title":"The pharmacogenomics global research network implementation working group: global collaboration to advance pharmacogenetic implementation","volume":"35","author":"Cavallari","year":"2025","journal-title":"Pharmacogenet Genomics"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/bcp.15591","article-title":"Implementation of pharmacogenomics: where are we now?","volume":"90","author":"Medwid","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2217\/pgs-2019-0004","article-title":"Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients","volume":"20","author":"Frigon","year":"2019","journal-title":"Pharmacogenomics"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1017\/S0016672315000099","article-title":"Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders","volume":"97","author":"Hess","year":"2015","journal-title":"Genet Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.1194006","article-title":"Science and regulation. Regulating direct-to-consumer personal genome testing","volume":"330","author":"McGuire","year":"2010","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/466817a","article-title":"Which way for genetic-test regulation? Assign regulation appropriate to the level of risk","volume":"466","author":"Javitt","year":"2010","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e1844","DOI":"10.1002\/hsr2.1844","article-title":"Knowledge, perceptions, and attitudes toward pharmacogenomics among pharmacists and pharmacy students: a systematic review","volume":"7","author":"Wondrasek","year":"2024","journal-title":"Health Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"31748","DOI":"10.1038\/s41598-024-82453-0","article-title":"A nationwide cross-sectional study in Saudi Arabia for the assessment of understanding and practices of clinicians towards personalized genetic testing","volume":"14","author":"Uddin","year":"2024","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/jpm12030425","article-title":"A scoping review of attitudes and experiences with Pharmacogenomic testing among patients and the general public: implications for patient counseling","volume":"12","author":"Allen","year":"2022","journal-title":"J Pers Med."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/tpj.2011.1","article-title":"Survey of US public attitudes toward pharmacogenetic testing","volume":"12","author":"Haga","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/qjmed\/hcaf035","article-title":"A United Kingdom nationally representative survey of public attitudes towards pharmacogenomics","volume":"118","author":"Magavern","year":"2025","journal-title":"QJM Mon J Assoc Physicians"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000217795","article-title":"Factors influencing uptake of pharmacogenetic testing in a diverse patient population","volume":"13","author":"O\u2019Daniel","year":"2010","journal-title":"Public Health Genomics"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2217\/pgs-2017-0191","article-title":"Patient perspectives following pharmacogenomics results disclosure in an integrated health system","volume":"19","author":"Lemke","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/tpj.2014.29","article-title":"Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients","volume":"15","author":"Lachance","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"ref22","year":"2026"},{"key":"ref23","year":"2026"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1085994","DOI":"10.3389\/fgene.2022.1085994","article-title":"Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved","volume":"13","author":"Gawronski","year":"2022","journal-title":"Front Genet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12920-022-01308-7","article-title":"Precision medicine from a citizen perspective: a survey of public attitudes towards pharmacogenomics in Flanders","volume":"15","author":"Edris","year":"2022","journal-title":"BMC Med Genet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e0192856","DOI":"10.1371\/journal.pone.0192856","article-title":"Awareness and attitude of the public toward personalized medicine in Korea","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/jpm12091398","article-title":"Development and validation of the Minnesota assessment of Pharmacogenomic literacy (MAPL)","volume":"12","author":"Allen","year":"2022","journal-title":"J Pers Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/pharmacy6040115","article-title":"Implementing clinical pharmacogenomics in the classroom: student pharmacist impressions of an educational intervention including personal genotyping","volume":"6","author":"Frick","year":"2018","journal-title":"Pharm Basel Switz"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40246-023-00509-0","article-title":"Knowledge, attitudes, and perceptions of the multi-ethnic population of the United Arab Emirates on genomic medicine and genetic testing","volume":"17","author":"Rahma","year":"","journal-title":"Hum Genomics"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s10038-020-0806-y","article-title":"Willingness to participate in genome testing: a survey of public attitudes from Qatar","volume":"65","author":"Abdul Rahim","year":"2020","journal-title":"J Hum Genet"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1887596\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:31:26Z","timestamp":1787549486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1887596\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":30,"alternative-id":["10.3389\/fpubh.2026.1887596"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1887596","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1887596"}}